December 24, 2013 | The Israeli Office of the Chief Scientist (OCS) has granted biomed company Cell Cure Neurosciences (a subsidiary of Bio Time) NIS 6.1 million. Cell Cure will use the funds to develop its OpRegen product, a cell-based treatment for age-related macular degeneration.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments